Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles

Alessia Bogni, Mario Monshouwer, Anna Moscone, Mats Hidestrand, Magnus Ingelman-Sundberg, Thomas Hartung, Sandra Coecke

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


A comparative metabolism study was performed for bufuralol, dextromethorphan, imipramine, mianserin, sparteine, tamoxifen, haloperidol and two drug candidates (Rec27/0110 and Rec15/2739) on V79 cells genetically engineered to express human cytochrome P450 (CYP) variants 2D6*1, 2D*2, 2D*9 and 2D*17. Unexpectedly, the CYP2D6*17 dependent metabolism profile of haloperidol and Rec27/0110 were found to differ from all other substrates tested. Some of these known standard substrates are frequently applied in marker reactions for CYP2D6 and with these standard substrates, CYP2D6*1 is known to be the most active form. In both cases of haloperidol and Rec27/0110 the variant form CYP2D6*17 had equal or higher activity compared to the CYP2D6*1 form. Results obtained with the V79 cells were confirmed using microsomal preparation of yeast cells expressing the variants CYP2D6*1 and CYP2D6*17 and CYP2D6 inhibitor quinidine. In conclusion, there is no general rule for a variant dependent metabolism profile by cytochrome P450 2D6 indicating that the activity profile of the CYP2D6 alleles may be substrate specific, thus may be reflected in pharmacokinetics consequences for individuals.

Original languageEnglish (US)
Pages (from-to)621-629
Number of pages9
JournalToxicology in Vitro
Issue number5
StatePublished - Aug 2005
Externally publishedYes


  • Cytochrome P450 2D6
  • Haloperidol
  • In vitro
  • Polymorphism
  • V79 Chinese hamster cells

ASJC Scopus subject areas

  • Toxicology


Dive into the research topics of 'Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles'. Together they form a unique fingerprint.

Cite this